Clinical Trial Update: Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson's Disease [Phase 1, Phase 2]

View source ↗

Summary

Open-label investigation assessing safety and clinical effects of NTCELL in Parkinson's disease across Phase 1 and Phase 2 trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• NTCELL (Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells)

Snippet

Sponsor: Living Cell Technologies | Conditions: Parkinson's Disease | Phase 1, Phase 2 | Status: COMPLETED